This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New York Group For Plastic Surgery Kicks Off Challenge To Benefit Cancer Organization

TARRYTOWN, N.Y., April 11, 2013 /PRNewswire/ --  Plastic and reconstructive surgeons Dr. C. Andrew Salzberg and Dr. R. Michael Koch of the New York Group for Plastic Surgery are spearheading a fundraising campaign to benefit FORCE (Facing Our Risk of Cancer Empowered), the only national nonprofit organization devoted to supporting women at hereditary risk for various cancers, including breast cancer.

Dr. Salzberg and Dr. Koch are being recognized by FORCE for the skill and compassion they provide to women undergoing mastectomy breast reconstruction to treat breast cancer, or to drastically reduce their risk with a prophylactic (preventive) mastectomy, an option chosen by more than one-third of high-risk women. Dr. Salzberg and Dr. Koch offer women a quicker, less uncomfortable process of mastectomy breast reconstruction known as Direct to Implant, or "One-Step," pioneered by Dr. Salzberg and practiced by both surgeons on hundreds of women who live locally or fly in from across the country to Westchester and Orange Counties for their care.

FORCE is honoring Dr. Salzberg and Dr. Koch as part of their national "Superheroes" fundraising campaign to support research, education and advocacy on behalf of people with hereditary breast, ovarian and other cancers. The New York Group for Plastic Surgery will kick off the campaign with an initial donation of $2,500, and individuals can donate to FORCE in Dr. Salzberg and Dr. Koch's honor by visiting http://www.firstgiving.com/fundraiser/salzberg-koch/heroes.

According to FORCE, 2.3 million women in the U.S. may be at increased risk for breast and ovarian cancer because of their family history. Women with a mutation in the BRCA (BReast CAncer) gene have up to an 85% lifetime risk for breast cancer and up to a 50% lifetime risk for ovarian cancer. It is estimated that 940,000 people in the U.S. carry a BRCA1 or BRCA2 gene mutation, which can be inherited from a mother or father.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs